The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:
- In 2011, almost 17,000 Americans died of drug overdose involving opioid analgesics.
- 1 in 20 high school seniors reports abusing OxyContin.
The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives course addresses this public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. ASAM's course also provides an additional unit addressing the common and complex overlap between opioid use and opioid addiction.
Over 5,200 learners have participated in the ER/LA opioid continuing education activities provided by ASAM. If you are interested in hosting a course for your organization, visit Host a Course.
Who Should Attend
The intended audience is all prescribers of ER/LA opioids which includes: pain specialists, primary care physicians, physician assistants, nurse practitioners, advanced practice nurses, dentists, addiction medicine physicians, psychiatrists and other physicians and clinicians.
- Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
- Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
- Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
- Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
- Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.
*This course is not intended to advocate for the use of ER/LA opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA opioids are the best course of treatment.
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ASAM designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASAM designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 3 AMA PRA Category 1 Credits™.
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.